Banque Transatlantique SA Takes $79.04 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Banque Transatlantique SA purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 151,935 shares of the medical research company’s stock, valued at approximately $79,041,000. Thermo Fisher Scientific accounts for about 1.9% of Banque Transatlantique SA’s portfolio, making the stock its 14th largest position.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $28,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $28,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $29,000. Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Finally, Endeavor Private Wealth Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $30,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.9 %

TMO opened at $423.69 on Friday. The business’s fifty day simple moving average is $476.15 and its 200 day simple moving average is $521.16. Thermo Fisher Scientific Inc. has a 52 week low of $409.85 and a 52 week high of $627.88. The firm has a market cap of $159.94 billion, a P/E ratio of 25.63, a PEG ratio of 2.99 and a beta of 0.86. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the business posted $5.11 earnings per share. The company’s revenue was up .2% on a year-over-year basis. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a $0.43 dividend. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Barclays dropped their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Raymond James reiterated an “outperform” rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Finally, Argus decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $607.43.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,200 shares of company stock valued at $13,235,041. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.